NEW YORK (Reuters) - Global stocks faltered on Tuesday as strong earnings from U.S. drugmakers Merck and Pfizer and expectations the Federal Reserve will cut rates was offset by a potential delay in a U.S.-China trade deal, which clouded sentiment and weakened the dollar.
European shares fell as companies headed toward their worst quarterly earnings in more than three years, according to the latest estimates by Refinitiv, underscoring concerns about the deteriorating health of Europe Inc.
The U.S. S&P 500 index eked out a fresh record intraday high, led by Merck and Pfizer, though a disappointing profit report from Google parent Alphabet kept the technology-rich Nasdaq in the red.
The benchmark index had breached its all-time high set in July on Monday, spurred by hopes of a U.S.-China trade deal and the likelihood of further stimulus from the U.S. central bank on Wednesday when it concludes a two-day meeting of policy-makers.
The steepening of the two- and 10-year yield curve suggests a budding risk-on sentiment among investors, now that some form of a U.S.-China trade agreement is likely, said Yousef Abbasi, global market strategist at INTL FCStone Financial in New York.
The spread in the yield curve US2US10=TWEB has gained about 20 basis points since leaving negative territory, a recession indicator, in early September.
However, a U.S. administration official said on Tuesday that an interim trade agreement might not be completed in time for signing in Chile next month as expected, while adding that did not mean the accord is falling apart.
Technology .SPLRCT shares, a sector of the S&P 500 that has been closely tied to trade progress, fell 0.92%.
Drugmakers Merck & Co Inc (MRK.N) and Pfizer Inc (PFE.N) rose after reporting upbeat third-quarter results, gaining 3.5% and 2.5%, respectively. The healthcare sector .SPXHC, which has been the second-worst performer among the 11 major S&P 500 sectors this year, rose 1.16% as the session’s best performer. A rotation into value stocks that investors have posited for months seems be taking hold, Abbasi said, pointing to recent gains in the SPDR S&P Regional Banking ETF (KRE) as evidence. The ETF has traded below 56 since May and could be set for further upside after a recent rally from below 50, he said.
“We’re seeing some of those high-flying tech names struggle,” Abbasi said. “We’re getting that risk-on move from sectors that have been ignored all year, the sectors that haven’t been loved.”
MSCI’s gauge of stocks across the globe gained 0.05%, while the pan-European STOXX 600 index lost 0.16%. MSCI’s emerging markets index .MSCIEF rose 0.07%.
On Wall Street, the Dow Jones Industrial Average .DJI fell 19.26 points, or 0.07%, to 27,071.46. The S&P 500 .SPX lost 2.53 points, or 0.08%, to 3,036.89 and the Nasdaq Composite .IXIC dropped 49.14 points, or 0.59%, to 8,276.85.
Oil pared losses amid expectations that U.S. refined product stockpiles declined last week.
Brent crude LCOc1 rose 2 cents to settle at $61.59 a barrel, while U.S. West Texas Intermediate CLc1 crude settled down 27 cents to $55.54.
Benchmark 10-year U.S. notes rose 4/32 in price to yield 1.8367%.
Asia stock markets: here
Asia-Pacific valuations: here
Reporting by Herbert Lash; Editing by Bernadette Baum and Sonya Hepinstall